Press "Enter" to skip to content

Exclusive: Novartis pitches discounts on pricey gene therapy for deadly muscle disorder

Novartis AG is offering price discounts in negotiations with U.S. health insurers on its gene therapy for spinal muscular atrophy (SMA), a treatment that could cost more than a million dollars, but the gesture comes with strings attached.

Original source:

Also Read:   Freeport-McMoRan workers at New Mexico mine test positive for COVID-19